Replimune opened lower at $21.32, compared with its previous close of $21.78. In the last trading session, the stock traded between $20.48 and $22.10. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Replimune is now worth
$ 65.23
Resulting in a loss of
$ 34.77 (34.77%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.21 (+0.96%)
Day High
$22.10
Day Low
$20.48
Day Open
$21.32
Prev Close
$21.78
Volume
23,89,994
1W Return
6.33%
1M Return
68.25%
3M Return
60.93%
6M Return
487.94%
1Y Return
140.84%
Fundamentals
Market Cap ($ Mn)
2,085
PE Ratio
-
PB Ratio
12.32
PEG Ratio
-
ROE
-59.43%
ROCE
-48.85%
EPS (TTM)
$-0.60
Investment Returns
1 Week
6.33%
1 Month
68.25%
3 Months
60.93%
6 Months
487.94%
9 Months
183.36%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
5Oct
Replimune class action deadline: Investors must act by October 5
Lead plaintiff deadline for Replimune class action is October 5, 2026. Class period covers purchases between October 20, 2025 and April 10, 2026. Stock declined approximately 84% from high of $10.73 to $1.70. Lawsuit alleges failure to disclose FDA study design deficiencies for RP1.
1mo ago
2Oct
Replimune announces TUDRIQEV commercial availability in US
Replimune Group announced commercial availability of TUDRIQEV in the US. TUDRIQEV is indicated with nivolumab for advanced cutaneous melanoma post-PD-1 progression. Approval based on IGNYTE trial showing 24.2% objective response rate. Median duration of response was 14.1 months in efficacy-evaluable patients. Confirmatory Phase 3 trial IGNYTE-3 is ongoing to verify clinical benefit.
1mo ago
17Sep
Replimune shareholders approve doubling of authorized common shares
Replimune stockholders approved increasing authorized common shares from 150 million to 300 million. The amendment becomes effective on September 15. The move provides flexibility for future capital raises or M&A activity.
1mo ago
20Aug
Replimune grants $15.58 strike options and RSUs to CCO DiNapoli
Replimune Group Inc has granted significant equity compensation to its new Chief Commercial Officer, Michelle DiNapoli. The package includes 150,000 stock options at a $15.58 strike price and 100,000 RSUs, structured to vest over four years. The grants were approved under Nasdaq Listing Rule 5635(c)(4) for employment inducement purposes.
2mo ago
15Aug
Replimune files shelf prospectus with SEC for future offerings
Replimune Group Inc submitted a shelf registration statement to the SEC. This regulatory step permits future securities offerings, though the filing omitted specific details regarding the offering size or immediate capital requirements.
3mo ago
14Aug
Replimune Q1 EPS $(0.72) beats estimate; FDA approves TUDRIQEV
Replimune Group reported Q1 EPS of $(0.72), beating estimates by 1.37%. Net loss narrowed to $69.8 million on cost cuts. FDA approved TUDRIQEV for melanoma treatment, marking a key commercial milestone.
